Measure Title | Measure Description | Used among Practices (Mean %) | Standard Deviation |
---|---|---|---|
Clinical process/effectiveness | |||
Antidepressant medication management | Percentage of patients ≥18 years old who were diagnosed with major depression and treated with antidepressant medication and who remained on antidepressant medication treatment | 59.9 | 8.7 |
Asthma: use of appropriate medications | Percentage of patients 5–64 years old who were identified as having persistent asthma and were appropriately prescribed controller medication | 48.0 | 9.8 |
BP control | Percentage of patients 18–85 years old with a diagnosis of hypertension and whose BP was <140/90 mm Hg | 69.9 | 10.7 |
Cancer screening | |||
Breast | Percentage of women 50–75 years old who had a mammogram to screen for breast cancer | 60.2 | 15.6 |
Cervical | Percentage of women 21–64 years old who received one or more Papanicolaou tests to screen for cervical cancer | 48.5 | 16.3 |
Colorectal | Percentage of adults 50–75 years old who had appropriate screening for colorectal cancer | 54.2 | 16.7 |
Diabetes | |||
Poor control of hemoglobin A1C | Percentage of patients 18–75 years old with diabetes without a recent hemoglobin A1C or hemoglobin A1C >9.0% | 40.7 | 12.9 |
LDL-C management | Percentage of patients 18–75 years old with diabetes whose LDL-C was <100 mg/dL | 62.1 | 10.2 |
Urine protein screening | Percentage of patients 18–75 years old with diabetes who had a nephropathy screening test or evidence of nephropathy | 78.4 | 11.0 |
Heart failure | |||
ACE inhibitor or ARB therapy | Percentage of patients aged ≥18 years with a diagnosis of heart failure who were prescribed an ACE inhibitor or ARB therapy | 55.4 | 11.9 |
β-Blocker therapy | Percentage of patients aged ≥18 years with a diagnosis of heart failure who were prescribed β-blocker therapy | 57.9 | 14.0 |
Ischemic vascular disease | |||
Use of aspirin or another antithrombotic | Percentage of patients 20–79 years old or older with a diagnosis of ischemic vascular disease who had documentation of use of aspirin or another antithrombotic | 50.1 | 19.5 |
LDL control | Percentage of patients 20–79 years old or older with a diagnosis of ischemic vascular disease whose LDL-C was <100 mg/dL | 65.4 | 8.5 |
Efficient use of health care resources | |||
Appropriate Treatment for Children with Upper Respiratory Infection (URI) | Percentage of children 3 months to 18 years old who were diagnosed with upper respiratory infection and were not dispensed an antibiotic prescription on the day of or 3 days after the episode | 62.5 | 26.0 |
Patient safety | |||
Use of high-risk medications in the elderly | Percentage of patients ≥66 years old who were not ordered high-risk medications | 80.1 | 6.6 |
Warfarin time in therapeutic range | Average percentage of time in which patients aged ≥18 years with atrial fibrillation on warfarin therapy have an INR within the therapeutic range in the past 45 days | 38.8 | 17.7 |
Population/public health | |||
Chlamydia screening for women | Percentage of women 16–24 years old who were identified as sexually active and who had at least one test for chlamydia | 12.9 | 15.0 |
Depression screening | Percentage of patients aged ≥18 years who were screened for clinical depression | 36.3 | 27.1 |
Influenza immunization | Percentage of patients aged ≥6 months seen for a visit in the past year who received an influenza immunization or who reported previous receipt of an influenza immunization | 29.5 | 12.3 |
Pneumococcal immunization for older adults | Percentage of patients ≥65 years old who have ever received a pneumococcal vaccine | 63.0 | 20.9 |
Tobacco use screening and cessation intervention | Percentage of patients aged ≥18 years who were screened for tobacco use within 24 months and who received cessation counseling intervention if identified as a tobacco user | 89.8 | 8.7 |
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; LDL-C, low-density lipoprotein cholesterol.